2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Bispecific Antibody Therapy, Non-Biological Therapies, Chemotherapy, Pharmacology, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Adult, Animal Model
PAPER

5629 Preclinical and clinical immune profiling of tacabrutideg (BGB-16673), a Bruton tyrosine kinase (BTK) degrader, shows preserved T-cell function and maintenance of key non-B-cell immune compartments in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)

Linlin Xu, Wei Xu2, Haitao Wang3, John F. Seymour, MBBS, PhD4, Meghan C. Thompson, MD5, Inhye E Ahn, MD6, Constantine S. Tam, MD,MBBS7, Ting Wang8, Lijie Zhang9, Wei Meng10, Bin Jiang11, Yaxin Zhang12, Si Mou13, Qiming Zhou14, Daniel Persky, MD15, Shelonitda Rose16, Wei Jin17, Teiko Sumiyoshi18, Zhirong Shen, PhD19
1 BeOne Medicines, Ltd, San Carlos, CA, United States
2 BeOne Medicines, Ltd, Beijing, China
3 BeOne Medicines, Ltd, Beijing, China
4 Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne, Melbourne, VIC, Australia
5 Memorial Sloan Kettering Cancer Center, New York, NY, United States
6 Dana-Farber Cancer Institute, Boston, MA, United States
7 Alfred Hospital and Monash University, Melbourne, VIC, Australia
8 BeOne Medicines, Ltd, Beijing, China
9 BeOne Medicines, Ltd, Beijing, China
10 BeOne Medicines, Ltd, Beijing, China
11 BeOne Medicines, Ltd, Beijing, China
12 BeOne Medicines, Ltd, Beijing, China
13 BeOne Medicines, Ltd, Beijing, China
14 BeOne Medicines, Ltd, Shanghai, China
15 BeOne Medicines, Ltd, San Carlos, CA, United States
16 BeOne Medicines, Ltd, San Carlos, CA, United States
17 BeOne Medicines, Ltd, Beijing, China
18 BeOne Medicines, Ltd, San Carlos, CA, United States
19 BeOne Medicines, Ltd, Shanghai, China

Introduction: Tacabrutideg (BGB-16673) is a potential first-in-class oral BTK degrader that induces BTK degradation through the proteasome pathway, leading to tumor regression. Tacabrutideg is currently being evaluated in the ongoing open-label, phase 1/2 CaDAnCe-101 study (BGB-16673-101; NCT05006716) in patients (pts) with B-cell malignancies. Infections remain an important consideration for pts with R/R CLL/SLL and for those receiving agents targeting B-cell receptor signaling, highlighting the need to understand treatment effects on broader non-B-cell compartments. Here we used preclinical selectivity, functional assays, and longitudinal clinical immune profiling to assess the impacts of tacabrutideg on selectivity and preservation of major non-B-cell immune compartments during treatment.

Methods: Ex vivo activity was evaluated using whole blood from healthy donors (n=6), incubated at 37°C for 16 hours with 160 nM of tacabrutideg, a clinically relevant concentration. After incubation, B cells, T cells, and neutrophils were isolated for proteomic analysis using liquid chromatography-tandem mass spectrometry. T-cell viability, proliferation, and activation were assessed in a staphylococcal enterotoxin B (SEB) stimulation assay using live/dead staining, carboxyfluorescein diacetate succinimidyl ester (CFSE) proliferation index, and IL-2 production, respectively. T-cell cytotoxic function was assessed in an EpCAM-CD3 T-cell engager–redirected killing assay against MKN45 cells. Clinical immune cell profiling was performed in pts with R/R CLL/SLL treated in the BGB-16673-101 trial using a validated TBNK flow cytometry panel. Absolute counts of CD19+ B cells, CD3+ T cells, CD4+ and CD8+ T-cell subsets, CD3−CD56+/CD16+ natural killer (NK) cells, and CD14+ monocytes were assessed at baseline and months 1, 6, 9, and 15. The analysis included 35 pts with evaluable baseline assessments and ≥1 post-baseline assessment. Data cutoff was March 25, 2026.

Results: In whole-blood proteomic profiling, tacabrutideg induced BTK degradation in BTK-expressing B cells and neutrophils. No off-target protein degradation was observed in T cells, which do not express BTK, demonstrating no off-target degradation with tacabrutideg. Tacabrutideg did not adversely affect T-cell viability, CFSE-defined T-cell proliferation, or IL-2 production in the SEB stimulation assay, and tacabrutideg did not impair T-cell mediated tumor-cell killing in the CD3 T-cell engager assay. Clinical immune cell profiles were available for 35 pts at baseline and for 30, 23, 21, and 5 pts at months 1, 6, 9, and 15, respectively. Tacabrutideg induced substantial and sustained depletion of CD19+ B-cells with median counts decreasing from 20,664 cells/µL at baseline and 20,836 cells/µL at month 1, to 5741, 2405, and 252 cells/µL at months 6, 9, and 15, respectively. In contrast, non-B-cell immune compartments remained broadly preserved and showed no statistically significant (p>0.05) changes from baseline. Median CD3+ T cell counts were 1925, 2839, 1494, 1755, and 1483 cells/µL at baseline and months 1, 6, 9, and 15, respectively. Corresponding median CD4+ T cell counts were 1017, 1328, 798, 813, and 686 cells/µL and median CD8+ T cell counts were 869, 1123, 676, 736, and 767 cells/µL. The median CD4:CD8 T cell ratio remained stable at 1.1, 1.2, 1.1, 1.0, and 0.9 across the same timepoints. Median NK cell counts were 214, 200, 168, 192, and 78 cells/µL, and median CD14+ monocyte counts were 346, 399, 275, 331, and 375 cells/µL, at baseline and months 1, 6, 9, and 15, respectively. Overall, tacabrutideg selectively depleted CD19+ B cells while quantitatively preserving T-cell subsets, NK cells, and monocytes.

Conclusions: These findings support a selective immune profile for tacabrutideg, characterized by expected B-cell depletion without evidence of broad host immune cell depletion of evaluated non–B-cell immune compartments. Preclinical assays showed preservation of T-cell viability and proliferation, IL-2 production, and T-cell–mediated killing, while clinical TBNK profiling showed maintenance of the T-cell, NK-cell, and monocyte compartments in pts with CLL treated with tacabrutideg. These data suggest that tacabrutideg has no major adverse impact on T cells, NK cells and monocytes.

Linlin Xu: BeOne Medicines, Ltd - Stock (publicly traded); BeOne Medicines, Ltd - Current Employment